Tag: Howard Shelanski
Firms act on Hengrui-GSK USD12.5bn drug development deal
Jiangsu Hengrui and GSK reached a USD12.5bn deal, with Cooley, Davis Polk and Han Kun advising
Trio acts on Nippon Paint’s USD2.3bn chemical deal
Davis Polk, Gibson Dunn, and Katzke & Morgenbesser advise on Nippon Paint’s $2.3B acquisition of AOC, owned by Lone Star Funds
Trio acts on Rio Tinto’s USD6.7bn lithium acquisition
Rio Tinto is acquiring Arcadium Lithium for $6.7 billion, pending regulatory approval
